SG11201602679VA - Stable polypeptides binding to human complement c5 - Google Patents

Stable polypeptides binding to human complement c5

Info

Publication number: SG11201602679VA
Authority: SG; Singapore
Prior art keywords: human complement; polypeptides binding; stable polypeptides; stable; binding
Prior art date: 2013-08-28

Application number

SG11201602679VA

Inventor

Joakim Nilsson

Erik Nordling

Patrik Strömberg

Original Assignee

Swedish Orphan Biovitrum Ab Publ

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-08-28

Filing date

2014-08-28

Publication date

2016-05-30

2014-08-28 Application filed by Swedish Orphan Biovitrum Ab Publ filed Critical Swedish Orphan Biovitrum Ab Publ

2016-05-30 Publication of SG11201602679VA publication Critical patent/SG11201602679VA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Zoology (AREA)
Immunology (AREA)
Toxicology (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Ophthalmology & Optometry (AREA)
Neurology (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Transplantation (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Peptides Or Proteins (AREA)

SG11201602679VA 2013-08-28 2014-08-28 Stable polypeptides binding to human complement c5 SG11201602679VA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE1350986		2013-08-28
PCT/EP2014/068282 WO2015028558A1 (en)	2013-08-28	2014-08-28	Stable polypeptides binding to human complement c5

Publications (1)

Publication Number	Publication Date
SG11201602679VA true SG11201602679VA (en)	2016-05-30

Family

ID=51539238

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201602679VA SG11201602679VA (en)	2013-08-28	2014-08-28	Stable polypeptides binding to human complement c5

Country Status (29)

Country	Link
US (1)	US9994626B2 (en)
EP (2)	EP3038633B1 (en)
JP (2)	JP6767865B2 (en)
KR (1)	KR102446636B1 (en)
CN (1)	CN105658228B (en)
AU (1)	AU2014314222B2 (en)
BR (1)	BR112016003142A2 (en)
CA (1)	CA2926976C (en)
CY (1)	CY1123732T1 (en)
DK (1)	DK3038633T3 (en)
ES (1)	ES2842105T3 (en)
HR (1)	HRP20210013T1 (en)
HU (1)	HUE052613T2 (en)
IL (1)	IL244218A (en)
LT (1)	LT3038633T (en)
MX (1)	MX382140B (en)
MY (1)	MY173804A (en)
NZ (1)	NZ718153A (en)
PH (1)	PH12016500371B1 (en)
PL (1)	PL3038633T3 (en)
PT (1)	PT3038633T (en)
RS (1)	RS61347B1 (en)
RU (2)	RU2020128977A (en)
SA (1)	SA516370622B1 (en)
SG (1)	SG11201602679VA (en)
SI (1)	SI3038633T1 (en)
SM (1)	SMT202100006T1 (en)
UA (1)	UA117933C2 (en)
WO (1)	WO2015028558A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RS58503B1 (en)	2012-02-20	2019-04-30	Swedish Orphan Biovitrum Ab Publ	Polypeptides binding to human complement c5
MX367423B (en) *	2013-08-28	2019-08-21	Affibody Ab	Binding polypeptides having a mutated scaffold.
LT3038633T (en) *	2013-08-28	2021-03-25	Ipc Research, Llc	STABLE POLYPEPTIDES WHICH BIND TO HUMAN COMPLEMENT C5
UY37651A (en) *	2017-03-31	2018-10-31	Swedish Orphan Biovitrum Ab Publ	IL-1R-I UNION POLYPEPTIDE
CN117327188A (en)	2017-07-11	2024-01-02	亚力兄制药公司	Polypeptide binding complement component C5 or serum albumin and fusion protein thereof
WO2022171892A1 (en) *	2021-02-15	2022-08-18	Affibody Ab	New her2-binding polypeptide
KR20240134857A (en) *	2021-11-01	2024-09-10	아이피씨 리써치, 엘엘씨	C5-binding protein administration
WO2024227886A1 (en)	2023-05-02	2024-11-07	Mebrahtu Aman	Bispecific binding molecule

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE509359C2 (en)	1989-08-01	1999-01-18	Cemu Bioteknik Ab	Use of stabilized protein or peptide conjugates for the preparation of a drug
US6074642A (en)	1994-05-02	2000-06-13	Alexion Pharmaceuticals, Inc.	Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
CA2424379C (en)	2000-10-10	2013-10-01	Tanox, Inc.	Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
AT410798B (en) *	2001-01-26	2003-07-25	Cistem Biotechnologies Gmbh	METHOD FOR IDENTIFYING, ISOLATING AND PRODUCING ANTIGENS AGAINST A SPECIFIC PATHOGEN
CN100391537C (en)	2001-08-17	2008-06-04	建南德克公司	Complement pathway inhibitors that bind to C5 and C5A but do not prevent C5B formation
ITMI20021527A1 (en)	2002-07-11	2004-01-12	Consiglio Nazionale Ricerche	C5 COMPONENT ANTIBODIES OF COMPLEMENT AND THEIR USE
EP1667702A2 (en)	2003-09-10	2006-06-14	Baxter International Inc., Baxter Healthcare Corp.	Peptides that inhibit complement activation
SE0400274D0 (en) *	2004-02-09	2004-02-09	Affibody Ab	New polypeptide
GB0518443D0 (en) *	2005-09-09	2005-10-19	Evolutec Ltd	Method of treating myasthenia gravis
DK1991275T3 (en) *	2006-03-08	2014-12-08	Archemix Llc	Complement aptamers AND ANTI-C5 AGENTS FOR USE IN THE TREATMENT OF EYE DISEASES
HUE066795T2 (en) *	2006-03-15	2024-09-28	Alexion Pharma Inc	Treatment of patients with paroxysmal nocturnal haemoglobinuria with a complement inhibitor
US8937153B2 (en)	2007-07-31	2015-01-20	Affibody Ab	Compositions, methods and uses
DK2231860T3 (en) *	2007-12-19	2011-12-05	Affibody Ab	Polypeptide derived protein A and capable of binding PDGF
US9187535B2 (en)	2007-12-19	2015-11-17	Affibody Ab	Polypeptide derived from protein A and able to bind PDGF
EP2072525A1 (en)	2007-12-21	2009-06-24	Affibody AB	New polypeptides having affinity for HER2
MX2011001371A (en)	2008-08-05	2011-06-16	Novartis Ag	Compositions and methods for antibodies targeting complement protein c5.
EP2327725A1 (en)	2009-11-26	2011-06-01	InflaRx GmbH	Anti-C5a binding moieties with high blocking activity
WO2012004384A2 (en)	2010-07-09	2012-01-12	Affibody Ab	Polypeptides
RS58503B1 (en) *	2012-02-20	2019-04-30	Swedish Orphan Biovitrum Ab Publ	Polypeptides binding to human complement c5
JP5980104B2 (en)	2012-11-22	2016-08-31	三菱電機株式会社	Liquid crystal display device manufacturing method and liquid crystal display device manufacturing system
EP2935335B1 (en)	2012-12-19	2020-10-28	Affibody AB	New polypeptides
MX367423B (en) *	2013-08-28	2019-08-21	Affibody Ab	Binding polypeptides having a mutated scaffold.
LT3038633T (en) *	2013-08-28	2021-03-25	Ipc Research, Llc	STABLE POLYPEPTIDES WHICH BIND TO HUMAN COMPLEMENT C5

2014
- 2014-08-28 LT LTEP14765883.5T patent/LT3038633T/en unknown
- 2014-08-28 RU RU2020128977A patent/RU2020128977A/en unknown
- 2014-08-28 RS RS20210005A patent/RS61347B1/en unknown
- 2014-08-28 MX MX2016002397A patent/MX382140B/en unknown
- 2014-08-28 SI SI201431739T patent/SI3038633T1/en unknown
- 2014-08-28 MY MYPI2016700583A patent/MY173804A/en unknown
- 2014-08-28 CN CN201480057470.XA patent/CN105658228B/en active Active
- 2014-08-28 BR BR112016003142A patent/BR112016003142A2/en not_active Application Discontinuation
- 2014-08-28 JP JP2016537298A patent/JP6767865B2/en active Active
- 2014-08-28 EP EP14765883.5A patent/EP3038633B1/en active Active
- 2014-08-28 PT PT147658835T patent/PT3038633T/en unknown
- 2014-08-28 SM SM20210006T patent/SMT202100006T1/en unknown
- 2014-08-28 DK DK14765883.5T patent/DK3038633T3/en active
- 2014-08-28 EP EP20201264.7A patent/EP3811961B1/en active Active
- 2014-08-28 HU HUE14765883A patent/HUE052613T2/en unknown
- 2014-08-28 WO PCT/EP2014/068282 patent/WO2015028558A1/en not_active Ceased
- 2014-08-28 US US14/914,290 patent/US9994626B2/en active Active
- 2014-08-28 UA UAA201603124A patent/UA117933C2/en unknown
- 2014-08-28 KR KR1020167007498A patent/KR102446636B1/en active Active
- 2014-08-28 HR HRP20210013TT patent/HRP20210013T1/en unknown
- 2014-08-28 NZ NZ718153A patent/NZ718153A/en unknown
- 2014-08-28 AU AU2014314222A patent/AU2014314222B2/en active Active
- 2014-08-28 ES ES14765883T patent/ES2842105T3/en active Active
- 2014-08-28 CA CA2926976A patent/CA2926976C/en active Active
- 2014-08-28 PL PL14765883T patent/PL3038633T3/en unknown
- 2014-08-28 SG SG11201602679VA patent/SG11201602679VA/en unknown
- 2014-08-28 RU RU2016111115A patent/RU2733897C2/en active
2016
- 2016-02-22 IL IL244218A patent/IL244218A/en active IP Right Grant
- 2016-02-24 PH PH12016500371A patent/PH12016500371B1/en unknown
- 2016-02-25 SA SA516370622A patent/SA516370622B1/en unknown
2020
- 2020-07-01 JP JP2020113725A patent/JP2020172505A/en active Pending
- 2020-12-30 CY CY20201101229T patent/CY1123732T1/en unknown

Also Published As

Publication number	Publication date
PH12016500371A1 (en)	2016-05-02
EP3811961B1 (en)	2025-08-20
SA516370622B1 (en)	2018-12-23
PL3038633T3 (en)	2021-07-19
UA117933C2 (en)	2018-10-25
JP6767865B2 (en)	2020-10-14
EP3038633B1 (en)	2020-10-14
NZ718153A (en)	2022-05-27
MY173804A (en)	2020-02-24
HUE052613T2 (en)	2021-05-28
LT3038633T (en)	2021-03-25
KR102446636B1 (en)	2022-09-23
US9994626B2 (en)	2018-06-12
AU2014314222A1 (en)	2016-04-21
BR122023020080A2 (en)	2023-12-26
CA2926976C (en)	2023-11-28
JP2016529270A (en)	2016-09-23
CN105658228A (en)	2016-06-08
HK1225656A1 (en)	2017-09-15
RU2016111115A3 (en)	2018-04-25
MX382140B (en)	2025-03-13
CA2926976A1 (en)	2015-03-05
RU2020128977A (en)	2021-11-30
SI3038633T1 (en)	2021-05-31
WO2015028558A1 (en)	2015-03-05
PH12016500371B1 (en)	2016-05-02
RS61347B1 (en)	2021-02-26
JP2020172505A (en)	2020-10-22
EP3811961A1 (en)	2021-04-28
US20160311870A1 (en)	2016-10-27
DK3038633T3 (en)	2021-01-11
MX2016002397A (en)	2016-09-08
SMT202100006T1 (en)	2021-03-15
KR20160048121A (en)	2016-05-03
IL244218A (en)	2017-11-30
IL244218A0 (en)	2016-04-21
RU2016111115A (en)	2017-10-03
CN105658228B (en)	2020-02-07
RU2733897C2 (en)	2020-10-09
AU2014314222B2 (en)	2018-05-24
BR112016003142A2 (en)	2017-10-17
ES2842105T3 (en)	2021-07-12
HRP20210013T1 (en)	2021-04-02
EP3038633A1 (en)	2016-07-06
PT3038633T (en)	2021-01-14
CY1123732T1 (en)	2021-10-29

Publication	Publication Date	Title
IL304738A (en)	2023-09-01	Hyperglycosylated binding polypeptides
IL267724B (en)	2022-05-01	Polypeptides binding to human complement c5
IL240838A0 (en)	2015-10-29	Anti-lag-3 binding proteins
IL244218A (en)	2017-11-30	Stable polypeptides binding to human complement c5
PL2839750T3 (en)	2018-06-29	Fat composition
SG11201604663SA (en)	2016-07-28	Cd44 binding peptides
PL2956010T5 (en)	2025-02-17	Fat composition
GB201310918D0 (en)	2013-07-31	Prosthesis
ZA201507808B (en)	2017-02-22	Binding element
ZA201600535B (en)	2017-05-31	Cosmetic composition
EP3007784A4 (en)	2016-12-07	Snowboard
SG11201508627XA (en)	2015-11-27	Peptides binding to parallel-stranded g-quadruplexes
GB201303977D0 (en)	2013-04-17	Binding polypeptides
GB201318147D0 (en)	2013-11-27	Herbal composition
GB201318146D0 (en)	2013-11-27	Herbal composition
GB201310949D0 (en)	2013-07-31	Binding Motif
TWM475270U (en)	2014-04-01	Natural extract dressing